Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
1.150
0.00 (0.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Cytosorbents Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cytosorbents stock have an average target of 4.67, with a low estimate of 1.00 and a high estimate of 10. The average target predicts an increase of 306.09% from the current stock price of 1.15.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 13, 2025.
Analyst Ratings
The average analyst rating for Cytosorbents stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +769.57% | Jan 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +769.57% | Jan 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +769.57% | Nov 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $1 | Hold | Reiterates | $1 | -13.04% | Nov 11, 2024 |
| EF Hutton | EF Hutton | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +769.57% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
39.70M
from 36.35M
Increased by 9.20%
Revenue Next Year
44.32M
from 39.70M
Increased by 11.64%
EPS This Year
-0.30
from -0.64
EPS Next Year
-0.21
from -0.30
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 41.8M | 47.8M | 61.9M | |||
| Avg | 39.7M | 44.3M | 54.0M | |||
| Low | 37.4M | 41.2M | 47.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 14.9% | 20.5% | 39.7% | |||
| Avg | 9.2% | 11.6% | 21.8% | |||
| Low | 2.9% | 3.8% | 7.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.30 | -0.15 | 0.02 |
| Avg | -0.30 | -0.21 | -0.09 |
| Low | -0.29 | -0.26 | -0.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.